3 Reasons to Avoid Shares of Valeant Pharmaceuticals

The company has done everything right over the past five years. But this may not be a bet worth taking.

The Motley Fool

Over the past five years, few Canadian stocks have been on as nice a run as Valeant Pharmaceuticals (TSX: VRX)(NYSE: VRX). Since this time in 2009, the stock has returned over 60% per year to shareholders. The company is undeniably the darling of the Canadian healthcare sector.

On Thursday morning, the company again reported strong results. Cash earnings came in at $1.72 per share, up 35% year-over-year. Revenue jumped by 77% to $1.89 billion.

Furthermore, Valeant is confident it can succeed in its $50 billion takeover attempt of Allergan (NYSE: AGN), best known for anti-wrinkle treatment Botox. Given Valeant CEO Michael Pearson’s track record of great acquisitions, this would also likely be great news for shareholders. And in this case Mr. Pearson even has the endorsement of activist investor Bill Ackman.

But before you buy Valeant’s shares, there are some things you must consider. Below are the top three reasons to steer clear of Valeant stock.

1. Uncertainty

Valeant’s business model rests on making numerous acquisitions to fill its pipeline, something that the company has done very well thus far. But this means the future is always very uncertain for the company. What happens if no suitable targets can be found? Will Mr. Pearson still feel the need to act? Analysts routinely say that Valeant is the most difficult stock to make projections for.

Valeant’s stock currently trades at just over $140 per share, which is an expensive price, considering the company made less than $7 in cash earnings per share in 2013. The market is clearly pricing in future successful acquisitions. So this makes Valeant much more speculative than most stocks on the TSX.

2. Accounting issues

Valeant’s acquisitive business model naturally leads to accounting discrepancies. For example, the company hardly needs to spend any money at all on research and development, leading to margins that appear high.

Furthermore, many of the accounting measures that Valeant presents are adjusted numbers, rather than standard accounting figures. More specifically, measures such as adjusted operating cash flow and cash earnings per share strip out certain acquisition-related costs, even though these costs are a central part of the company’s business model.

To be clear, there is nothing fraudulent about these numbers. But it does require an extra level of caution and scrutiny from investors.

3. Other alternatives

Owning shares of Valeant is akin to handing money over to Mr. Pearson, and trusting him to spend it wisely. So far he has. But there are other companies that have just as good a track record. The best example in Canada is Constellation Software, where CEO Mark Leonard has an excellent track record of buying small software companies.

I am not saying that Valeant shares will go down, or even that they’re overpriced. But they are very speculative, and buying the shares is a bet simply not worth taking when there are so many great alternatives.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair holds no positions in any of the stocks mentioned in this article. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Nuclear power station cooling tower
Metals and Mining Stocks

If You’d Invested $1,000 in Cameco Stock 5 Years Ago, This Is How Much You’d Have Now

Cameco (TSX:CCO) stock still looks undervalued, despite a 258% rally. Can the uranium miner deliver more capital gains to shareholders?

Read more »

Businessman holding tablet and showing a growing virtual hologram of statistics, graph and chart with arrow up on dark background. Stock market. Business growth, planning and strategy concept
Dividend Stocks

TFSA Magic: Earn Enormous Passive Income That the CRA Can’t Touch

If you're seeking out passive income, with zero taxes involved, then get on board with a TFSA and this portfolio…

Read more »

Man with no money. Businessman holding empty wallet
Dividend Stocks

2 Stocks Under $50 New Investors Can Confidently Buy

There are some great stocks under $50 that every investor needs to know about. Here’s a look at two great…

Read more »

potted green plant grows up in arrow shape
Stocks for Beginners

3 Growth Stocks I’m Buying in April

These three growth stocks are up in the last year, and that is likely to continue on as we keep…

Read more »

clock time
Tech Stocks

Long-Term Investing: 3 Top Canadian Stocks You Can Buy for Under $20 a Share

These three under-$20 stocks offer excellent buying opportunities for long-term investors.

Read more »

Arrowings ascending on a chalkboard
Energy Stocks

Beat the TSX With This Cash-Gushing Dividend Stock

Canadian Natural Resources stock is well set up to beat the TSX as it continues to generate strong cash flows…

Read more »

think thought consider
Dividend Stocks

Down 10.88%: Is ATD Stock a Good Buy After Earnings?

Alimentation Couche-Tard (TSX:ATD) stock might not be the easy buy-case it once was. Here’s a look at what happened.

Read more »

money cash dividends
Dividend Stocks

TFSA Dividend Stocks: Earn $1,200/Year Tax-Free

Canadian stocks like Fortis are a must-have in your portfolio to earn tax-free yields for decades.

Read more »